{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:19:42Z","timestamp":1761988782721,"version":"build-2065373602"},"reference-count":143,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2011-4709","2012-2288","2013-2546"],"award-info":[{"award-number":["2011-4709","2012-2288","2013-2546"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.bbapap.2015.01.009","type":"journal-article","created":{"date-parts":[[2015,1,22]],"date-time":"2015-01-22T06:04:17Z","timestamp":1421906657000},"page":"769-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Explorative and targeted neuroproteomics in Alzheimer's disease"],"prefix":"10.1016","volume":"1854","author":[{"given":"Ann","family":"Brinkmalm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Portelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"\u00d6hrfelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Gobom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbapap.2015.01.009_bb0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0010","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/349704a0","article-title":"Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease","volume":"349","author":"Goate","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0020","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.7638622","article-title":"Candidate gene for the chromosome 1 familial Alzheimer's disease locus","volume":"269","author":"Levy-Lahad","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0025","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/375754a0","article-title":"Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease","volume":"375","author":"Sherrington","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0030","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/oxfordjournals.jbchem.a135625","article-title":"One of the antigenic determinants of paired helical filaments is related to tau protein","volume":"99","author":"Nukina","year":"1986","journal-title":"J. Biochem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-8-20","article-title":"Fluid biomarkers in Alzheimer's disease \u2014 current concepts","volume":"8","author":"Rosen","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-2006-9S317","article-title":"Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal","volume":"9","author":"Hardy","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJMe1313943","article-title":"Antiamyloid therapy for Alzheimer's disease\u2014are we on the right road?","volume":"370","author":"Karran","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.molcel.2013.01.029","article-title":"The coming age of complete, accurate, and ubiquitous proteomes","volume":"49","author":"Mann","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3233\/JAD-2005-8407","article-title":"Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases","volume":"8","author":"Zhang","year":"2005","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0070","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0028-3908(00)00010-1","article-title":"Neuropeptides\u2014an overview","volume":"39","author":"Hokfelt","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-8454-5-10","article-title":"Multiplicity of cerebrospinal fluid functions: new challenges in health and disease","volume":"5","author":"Johanson","year":"2008","journal-title":"Cerebrospinal Fluid Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0080","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1471-4159.2009.06558.x","article-title":"An update on clinical proteomics in Alzheimer's research","volume":"112","author":"Korolainen","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","article-title":"Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders","volume":"9","author":"Abdi","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jprot.2014.04.028","article-title":"Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset","volume":"106","author":"Chiasserini","year":"2014","journal-title":"J. Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archneurol.2011.642","article-title":"Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations","volume":"69","author":"Ringman","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neurobiolaging.2004.03.012","article-title":"Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid","volume":"26","author":"Zhang","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0105","doi-asserted-by":"crossref","first-page":"e42555","DOI":"10.1371\/journal.pone.0042555","article-title":"Peptidome analysis of cerebrospinal fluid by LC\u2013MALDI MS","volume":"7","author":"Holtta","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1386207013331246","article-title":"Peptidomics: the comprehensive analysis of peptides in complex biological mixtures","volume":"4","author":"Schulz-Knappe","year":"2001","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jms.737","article-title":"Human cerebrospinal fluid peptidomics","volume":"40","author":"Yuan","year":"2005","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0120","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1021\/pr070501k","article-title":"Integrated analysis of the cerebrospinal fluid peptidome and proteome","volume":"7","author":"Zougman","year":"2008","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0125","doi-asserted-by":"crossref","first-page":"e26540","DOI":"10.1371\/journal.pone.0026540","article-title":"Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers","volume":"6","author":"Jahn","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ymeth.2012.03.018","article-title":"A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid","volume":"56","author":"Wijte","year":"2012","journal-title":"Methods"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0135","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1021\/ac702422x","article-title":"Relative quantification of proteins in human cerebrospinal fluids by MS\/MS using 6-plex isobaric tags","volume":"80","author":"Dayon","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0140","doi-asserted-by":"crossref","DOI":"10.1021\/pr500317d","article-title":"Multiplexed MRM with internal standards for cerebrospinal fluid candidate protein biomarker quantitation","author":"Percy","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0145","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1471-4159.2003.01747.x","article-title":"Biochemical and molecular studies using human autopsy brain tissue","volume":"85","author":"Hynd","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0150","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/archneur.63.1.38","article-title":"Neuropathologic substrate of mild cognitive impairment","volume":"63","author":"Markesbery","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0160","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s007020050174","article-title":"Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease","volume":"106","author":"Bigl","year":"1999","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0304-3940(94)90214-3","article-title":"Isolation of glyceraldehyde 3-phosphate dehydrogenase (Gapdh) cDNA from the distal half of mouse chromosome 16: further indication of a link between Alzheimer's disease and glycolysis","volume":"182","author":"Seipp","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000050753","article-title":"The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia","volume":"46","author":"Fukuyama","year":"2001","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4137\/JCNSD.S13821","article-title":"Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke","volume":"6","author":"Hjalmarsson","year":"2014","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3233\/JAD-2009-1075","article-title":"Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt\u2013Jakob disease","volume":"17","author":"Jesse","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0185","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3233\/JAD-2011-110566","article-title":"Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease","volume":"27","author":"Bjerke","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000323417","article-title":"Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease","volume":"1","author":"Ohrfelt","year":"2011","journal-title":"Dement. Geriatr. Cogn. Disord. Extra"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neulet.2004.07.061","article-title":"Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases","volume":"370","author":"Steinacker","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymeth.2013.04.008","article-title":"Recent advances in quantitative neuroproteomics","volume":"61","author":"Craft","year":"2013","journal-title":"Methods"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0205","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/pr3001546","article-title":"Label-free quantitative LC\u2013MS proteomics of Alzheimer's disease and normally aged human brains","volume":"11","author":"Andreev","year":"2012","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/prca.201100068","article-title":"Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease","volume":"6","author":"Donovan","year":"2012","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0215","doi-asserted-by":"crossref","first-page":"13256","DOI":"10.1074\/jbc.M314124200","article-title":"Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases","volume":"279","author":"Choi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0220","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2174\/156720508786898488","article-title":"Disease state, age, sex, and post-mortem time-dependent expression of proteins in AD vs. control frontal cortex brain samples","volume":"5","author":"Muller","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0225","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1021\/pr900474t","article-title":"Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease","volume":"8","author":"Gozal","year":"2009","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0230","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1021\/pr301146m","article-title":"Sources of technical variability in quantitative LC\u2013MS proteomics: human brain tissue sample analysis","volume":"12","author":"Piehowski","year":"2013","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0235","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1074\/mcp.M600162-MCP200","article-title":"Advances and challenges in liquid chromatography\u2013mass spectrometry-based proteomics profiling for clinical applications","volume":"5","author":"Qian","year":"2006","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0240","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/emm.2013.76","article-title":"Brain site-specific proteome changes in aging-related dementia","volume":"45","author":"Manavalan","year":"2013","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1559-0275-10-5","article-title":"Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains","volume":"10","author":"Begcevic","year":"2013","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuint.2012.12.001","article-title":"Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations","volume":"62","author":"Castano","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jalz.2012.04.009","article-title":"The synaptic proteome in Alzheimer's disease","volume":"9","author":"Chang","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0260","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jprot.2011.03.033","article-title":"Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects","volume":"74","author":"Di Domenico","year":"2011","journal-title":"J. Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0265","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/(SICI)1522-2683(19990101)20:4\/5<928::AID-ELPS928>3.0.CO;2-Z","article-title":"Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease","volume":"20","author":"Greber","year":"1999","journal-title":"Electrophoresis"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0270","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.nbd.2005.05.021","article-title":"Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain","volume":"20","author":"Korolainen","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2004.11.010","article-title":"Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain","volume":"27","author":"Korolainen","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0280","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1021\/pr401202d","article-title":"Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry","volume":"13","author":"Musunuri","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0285","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/prca.200800161","article-title":"Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis","volume":"3","author":"Perluigi","year":"2009","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0290","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L","article-title":"Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process","volume":"1","author":"Schonberger","year":"2001","journal-title":"Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0295","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/JAD-2007-11203","article-title":"Proteomics analysis of the Alzheimer's disease hippocampal proteome","volume":"11","author":"Sultana","year":"2007","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0300","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.neurobiolaging.2005.09.021","article-title":"Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD","volume":"27","author":"Sultana","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0305","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.nbd.2005.10.004","article-title":"Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach","volume":"22","author":"Sultana","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0310","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1582-4934.2007.00065.x","article-title":"Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study","volume":"11","author":"Sultana","year":"2007","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0315","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1023\/A:1020941929414","article-title":"Proteomic profiling and neurodegeneration in Alzheimer's disease","volume":"27","author":"Tsuji","year":"2002","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0320","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11064-013-1210-1","article-title":"Differential expression of proteins in brain regions of Alzheimer's disease patients","volume":"39","author":"Zahid","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0325","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","article-title":"The human plasma proteome: history, character, and diagnostic prospects","volume":"1","author":"Anderson","year":"2002","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0330","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/17520363.1.1.59","article-title":"Aspects of beta-amyloid as a biomarker for Alzheimer's disease","volume":"1","author":"Andreasson","year":"2007","journal-title":"Biomark. Med"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0335","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/alzrt82","article-title":"The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease","volume":"3","author":"Vassar","year":"2011","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0340","doi-asserted-by":"crossref","first-page":"29627","DOI":"10.1074\/jbc.R800010200","article-title":"Intramembrane proteolysis by gamma-secretase","volume":"283","author":"Steiner","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0345","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.neurobiolaging.2009.06.002","article-title":"A novel pathway for amyloid precursor protein processing","volume":"32","author":"Portelius","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0350","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0355","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/359325a0","article-title":"Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids","volume":"359","author":"Seubert","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0360","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0365","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1006\/bbrc.1994.1634","article-title":"Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid","volume":"200","author":"Tabaton","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0370","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.89.7.2551","article-title":"Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients","volume":"89","author":"Van Nostrand","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0375","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"Suppl. 1","key":"10.1016\/j.bbapap.2015.01.009_bb0380","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1471-4159.2011.07510.x","article-title":"Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?","volume":"120","author":"Nalivaeva","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0385","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.2174\/138161211797416039","article-title":"Novel abeta isoforms in Alzheimer's disease \u2014 their role in diagnosis and treatment","volume":"17","author":"Portelius","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0390","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/j.1471-4159.1993.tb09841.x","article-title":"Characterization of beta-amyloid peptide from human cerebrospinal fluid","volume":"61","author":"Vigo-Pelfrey","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0395","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/jms.2987","article-title":"An online nano-LC\u2013ESI\u2013FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid","volume":"47","author":"Brinkmalm","year":"2012","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0400","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt30","article-title":"A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease","volume":"2","author":"Portelius","year":"2010","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0410","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-132489","article-title":"Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry","volume":"41","author":"Korecka","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0415","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ab.2011.08.010","article-title":"Quantitation of amyloid beta peptides Abeta(1\u201338), Abeta(1\u201340), and Abeta(1\u201342) in human cerebrospinal fluid by ultra-performance liquid chromatography\u2013tandem mass spectrometry","volume":"419","author":"Lame","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0420","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3233\/JAD-2012-121471","article-title":"A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls","volume":"33","author":"Pannee","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.bbapap.2015.01.009_bb0425","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","article-title":"Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid","volume":"60","author":"Leinenbach","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0430","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainres.2013.03.019","article-title":"Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease","volume":"1513","author":"Brinkmalm","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0435","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/febs.12590","article-title":"The role of protein glycosylation in Alzheimer disease","volume":"281","author":"Schedin-Weiss","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0440","doi-asserted-by":"crossref","first-page":"11848","DOI":"10.1073\/pnas.1102664108","article-title":"Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein\/amyloid beta-peptides in human cerebrospinal fluid","volume":"108","author":"Halim","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0445","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/pr800758g","article-title":"Elucidation of O-glycosylation structures of the beta-amyloid precursor protein by liquid chromatography\u2013mass spectrometry using electron transfer dissociation and collision induced dissociation","volume":"8","author":"Perdivara","year":"2009","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0450","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.expneurol.2009.06.011","article-title":"Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid","volume":"223","author":"Portelius","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0455","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/ac3033239","article-title":"Quantification of amyloid precursor protein isoforms using quantification concatamer internal standard","volume":"85","author":"Chen","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0460","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/269604a0","article-title":"Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man","volume":"269","author":"Utermann","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0465","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1016\/S0021-9258(18)34702-1","article-title":"Human apolipoprotein E. The complete amino acid sequence","volume":"257","author":"Rall","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0470","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1016\/S0021-9258(19)52510-8","article-title":"Human E apoprotein heterogeneity. Cysteine\u2013arginine interchanges in the amino acid sequence of the apo-E isoforms","volume":"256","author":"Weisgraber","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0475","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0480","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1093\/hmg\/dds296","article-title":"Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease","volume":"21","author":"Cruchaga","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0485","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","article-title":"Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls","volume":"127","author":"Martinez-Morillo","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","article-title":"Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization","volume":"285","author":"Vanmechelen","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0495","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/pr7008669","article-title":"Characterization of tau in cerebrospinal fluid using mass spectrometry","volume":"7","author":"Portelius","year":"2008","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0500","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1373\/clinchem.2013.216515","article-title":"Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry","volume":"60","author":"McAvoy","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0505","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1074\/mcp.M114.040113","article-title":"Targeting synaptic pathology with a novel affinity mass spectrometry approach","volume":"13","author":"Brinkmalm","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0510","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1326-9-53","article-title":"SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease","volume":"9","author":"Brinkmalm","year":"2014","journal-title":"Mol. Neurodegener."},{"year":"2014","series-title":"Cerebrospinal Fluid Levels of the Synaptic Protein Neurogranin Predict Cognitive Decline in Prodromal Alzheimer's Disease, Alzheimers Dement","author":"Kvartsberg","key":"10.1016\/j.bbapap.2015.01.009_bb0515"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0520","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jneumeth.2014.02.016","article-title":"Quantitative multiple reaction monitoring analysis of synaptic proteins from human brain","volume":"227","author":"Chang","year":"2014","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0525","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuint.2014.05.011","article-title":"Targeted quantitative analysis of synaptic proteins in Alzheimer's disease brain","volume":"75","author":"Chang","year":"2014","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0530","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00726-010-0645-9","article-title":"Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry","volume":"40","author":"Skorobogatko","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0535","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0540","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0545","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","article-title":"Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility","volume":"13","author":"Mattsson","year":"2011","journal-title":"Neruomol. Med."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0550","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-2012-120787","article-title":"Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia","volume":"33","author":"Olsson","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0555","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1559-0275-10-19","article-title":"Chitotriosidase \u2014 a putative biomarker for sporadic amyotrophic lateral sclerosis","volume":"10","author":"Varghese","year":"2013","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0560","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1021\/ac400831z","article-title":"Mass spectrometry assessment of ubiquitin carboxyl-terminal hydrolase L1 partitioning between soluble and particulate brain homogenate fractions","volume":"85","author":"Chen","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0565","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.parkreldis.2014.01.011","article-title":"CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders","volume":"20","author":"Mondello","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0570","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1750-1326-7-41","article-title":"Mass spectrometry quantification of clusterin in the human brain","volume":"7","author":"Chen","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0575","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/pmic.201200010","article-title":"Targeted proteomics for quantification of histone acetylation in Alzheimer's disease","volume":"12","author":"Zhang","year":"2012","journal-title":"Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0580","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2013.05.003","article-title":"Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates","volume":"930","author":"Choi","year":"2013","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0585","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00726-006-0409-8","article-title":"Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects","volume":"32","author":"Fonteh","year":"2007","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0590","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clinbiochem.2012.12.019","article-title":"Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum","volume":"46","author":"Krastins","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0595","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1021\/pr101221h","article-title":"Serum clusterin levels are not increased in presymptomatic Alzheimer's disease","volume":"10","author":"IJsselstijn","year":"2011","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0600","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nbt1315","article-title":"Improving the success rate of proteome analysis by modeling protein-abundance distributions and experimental designs","volume":"25","author":"Eriksson","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0605","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1021\/ac301572t","article-title":"Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses","volume":"84","author":"McAlister","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0610","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1021\/pr0702060","article-title":"How shall we use the proteomics toolbox for biomarker discovery?","volume":"6","author":"Lescuyer","year":"2007","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0615","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/pmic.201300377","article-title":"Why have so few proteomic biomarkers \u201csurvived\u201d validation? (Sample size and independent validation considerations)","volume":"14","author":"Hernandez","year":"2014","journal-title":"Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0620","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/506150a","article-title":"Scientific method: statistical errors","volume":"506","author":"Nuzzo","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0625","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1074\/mcp.I500001-MCP200","article-title":"The roles of multiple proteomic platforms in a pipeline for new diagnostics","volume":"4","author":"Anderson","year":"2005","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0630","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nbt1235","article-title":"Protein biomarker discovery and validation: the long and uncertain path to clinical utility","volume":"24","author":"Rifai","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1373\/49.1.1","article-title":"Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy","volume":"49","author":"Bossuyt","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0640","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.0000000000000621","article-title":"Reporting standards for studies of diagnostic test accuracy in dementia: the STARDdem initiative","volume":"83","author":"Noel-Storr","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0645","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1179\/016164106X98035","article-title":"Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects","volume":"28","author":"Castano","year":"2006","journal-title":"Neurol. Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0650","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00001756-200204160-00015","article-title":"Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients","volume":"13","author":"Davidsson","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0655","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","article-title":"Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease","volume":"118","author":"Puchades","year":"2003","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0660","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1373\/clinchem.2006.078014","article-title":"Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease","volume":"53","author":"Korolainen","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0665","first-page":"281","article-title":"Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease","author":"Cheon","year":"2001","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0670","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JAD-2004-6306","article-title":"Proteome analysis of brain proteins in Alzheimer's disease: subproteomics following sequentially extracted protein preparation","volume":"6","author":"Shiozaki","year":"2004","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0675","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.neurobiolaging.2005.05.005","article-title":"Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis","volume":"27","author":"Sultana","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0680","doi-asserted-by":"crossref","first-page":"21522","DOI":"10.1074\/jbc.M502255200","article-title":"Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets","volume":"280","author":"Pamplona","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0685","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4088\/JCP.v67n0418","article-title":"Genetics, transcriptomics, and proteomics of Alzheimer's disease","volume":"67","author":"Papassotiropoulos","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0690","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nbd.2005.09.004","article-title":"Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling","volume":"21","author":"Emilsson","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0695","doi-asserted-by":"crossref","first-page":"e16266","DOI":"10.1371\/journal.pone.0016266","article-title":"Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease","volume":"6","author":"Twine","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2015.01.009_bb0700","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JAD-2005-7205","article-title":"Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease","volume":"7","author":"Zhang","year":"2005","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0705","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/NEN.0b013e3181f52e01","article-title":"Distribution and expression of picalm in Alzheimer disease","volume":"69","author":"Baig","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0710","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/1567205043332225","article-title":"The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease","volume":"1","author":"Vogelgesang","year":"2004","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bbapap.2015.01.009_bb0715","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00008571-200210000-00005","article-title":"Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans","volume":"12","author":"Vogelgesang","year":"2002","journal-title":"Pharmacogenetics"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963915000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963915000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:50:22Z","timestamp":1761609022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570963915000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":143,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1570963915000205"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2015.01.009","relation":{},"ISSN":["1570-9639"],"issn-type":[{"type":"print","value":"1570-9639"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Explorative and targeted neuroproteomics in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbapap.2015.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}